Table 2.
Detailed statistics of the BCR-free survival analysis according to the identified stratum combined with clinical parameters.
| Stratum | Clinical Variable | n0 | nevents | rmean (sermean) | Endtime | HR (95% CI) | p-Value | 2-Year BCR-Free Rate (95% CI) | 5-Year BCR-Free Rate (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 169 | 19 | 3602.05 (239.49) | 4604 | ref | 89% (84–95%) | 78% (67–90%) | ||
| 1 | 251 | 53 | 2198.3 (167.05) | 3524 | 2.2 (1.3–3.6) | 0.003 | 81% (75–87%) | 54% (42–68%) | |
| Lymph node status (pN) | |||||||||
| 0 | pN0 | 114 | 10 | 3707.84 (291.41) | 4606 | ref | 93% (87–99%) | 81% (69–96%) | |
| pN1 | 24 | 7 | 1443.27 (184.91) | 2040 | 3.17 (1.2–8.3) | 0.02 | 72% (55–94%) | 64% (46–91%) | |
| 1 | pN0 | 167 | 33 | 2202.1 (212.38) | 3524 | 2.58 (1.27–5.2) | 0.009 | 83% (76–90%) | 55% (41–74%) |
| pN1 | 44 | 13 | 1070.09 (99.5) | 1506 | 4.65 (2.02–10.7) | <0.001 | 74% (60–91%) | - | |
| Gleason score | |||||||||
| 0 | 6 | 18 | 0 | 1436 (-) | 1436 | - | - | - | |
| 7A | 56 | 2 | 4244.59 (269.05) | 4604 | ref | 98% (94–100%) | 90% (75–100%) | ||
| 7B | 28 | 2 | 1714.53 (139.46) | 1925 | 2.91 (0.41–20.7) | 0.3 | 95% (85–100%) | 84% (65–100%) | |
| 8 | 26 | 4 | 2086.41 (217.07) | 2576 | 5.77 (1.05–31.6) | 0.043 | 78% (61–100%) | 78% (61–100%) | |
| 9 | 41 | 11 | 1933.1 (218.99) | 2859 | 7.42 (1.64–33.5) | 0.009 | 79% (66–95%) | 62% (44–87%) | |
| 1 | 6 | 21 | 2 | 2336.27 (186.78) | 2620 | 2.56 (0.36–18.2) | 0.3 | 87% (71–100%) | 87% (71–100%) |
| 7A | 65 | 4 | 2863.35 (395.79) | 3524 | 2.43 (0.44–13.3) | 0.3 | 93% (86–100%) | 70% (39–100%) | |
| 7B | 54 | 11 | 1555.68 (155.16) | 2211 | 7.43 (1.65–33.6) | 0.009 | 85% (74–97%) | 48% (27–85%) | |
| 8 | 33 | 7 | 2439.79 (274.56) | 3253 | 9.05 (1.88–43.7) | 0.006 | 73% (57–94%) | 73% (57–94%) | |
| 9 | 75 | 29 | 1582.5 (230.84) | 3447 | 13.7 (3.27–57.4) | <0.001 | 69% (58–82%) | 36% (21–61%) | |
| 10 | 3 | 0 | 1065 (-) | 1065 | - | - | - | ||
| TNM (EAU risk groups for BCR) | |||||||||
| 0 | cT1-2a | 5 | 0 | 1815 (-) | 1815 | - | - | - | |
| cT2b | 6 | 0 | 2753 (-) | 2753 | - | - | - | ||
| cT2c-4 | 156 | 19 | 3489.94 (264.72) | 4604 | ref | 88% (82–95%) | 75% (63–89%) | ||
| 1 | cT1-2a | 2 | 0 | 2620 (-) | 2620 | - | - | - | |
| cT2b | 3 | 0 | 2553 (-) | 2553 | - | - | - | ||
| cT2c-4 | 243 | 53 | 2110.36 (179.47) | 3524 | 2.05 (1.21–3.46) | 0.008 | 80% (74–86%) | 51% (39–67%) | |
| Stage (EAU risk groups for BCR) | |||||||||
| 0 | Localized | 70 | 0 | 4604 (-) | 4604 | - | - | - | |
| Locally advanced | 97 | 19 | 1982.45 (175.46) | 2859 | ref | 83% (74–92%) | 62% (46–83%) | ||
| 1 | Localized | 83 | 9 | 2817.88 (241.55) | 3524 | 1.5 (0.87–2.57) | 0.14 | 88% (79–97%) | 74% (58–96%) |
| Locally advanced | 165 | 44 | 1870.44 (195.09) | 3447 | 0.61 (0.28–1.36) | 0.2 | 77% (70–85%) | 42% (28–64%) | |
| Preoperative PSA groups | |||||||||
| 0 | <10 ng/mL | 108 | 12 | 3707.59 (273.11) | 4604 | ref | 87% (80–95%) | 77% (63–94%) | |
| 10–20 ng/mL | 19 | 2 | 1628.96 (149.93) | 2056 | 1.03 (0.36–2.93) | 0.9 | 97% (91–100%) | 72% (50–100%) | |
| >20 ng/mL | 36 | 5 | 1739.72 (127.6) | 1860 | 0.82 (0.18–3.69) | 0.8 | 83% (63–100%) | 83% (63–100%) | |
| 1 | <10 ng/mL | 171 | 31 | 2301.4 (212.54) | 3524 | 1.79 (0.92–3.49) | 0.088 | 83% (76–90%) | 53% (38–75%) |
| 10–20 ng/mL | 49 | 12 | 2206.48 (291.11) | 2364 | 2.23 (1–4.97) | 0.049 | 74% (60–91%) | 54% (36–82%) | |
| >20 ng/mL | 24 | 8 | 1495.88 (225.37) | 3447 | 2.83 (1.16–6.94) | 0.023 | 76% (60–91%) | 51% (27–98%) | |